

Resource Summary Report

Generated by [RRID](#) on Aug 6, 2026

CD19 Antibody, anti-human, PE-Vio® 770, REAfinity™

RRID:AB_2726200

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-113-647, RRID:AB_2726200

Antibody Information

URL: http://antibodyregistry.org/AB_2726200

Proper Citation: Miltenyi Biotec Cat# 130-113-647, RRID:AB_2726200

Target Antigen: CD19

Host Organism: human

Clonality: monoclonal

Comments: Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-110-251. (RRID:AB_2655813).

Antibody Name: CD19 Antibody, anti-human, PE-Vio® 770, REAfinity™

Description: This monoclonal targets CD19

Target Organism: human

Clone ID: clone REA675

Antibody ID: AB_2726200

Vendor: Miltenyi Biotec

Catalog Number: 130-113-647

Record Creation Time: 20250819T211742+0000

Record Last Update: 20250819T222927+0000

Ratings and Alerts

No rating or validation information has been found for CD19 Antibody, anti-human, PE-Vio® 770, REAfinity™.

No alerts have been found for CD19 Antibody, anti-human, PE-Vio® 770, REAfinity™.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Barozzi D, et al. (2025) Dynamic stimulation promotes functional tissue-like organization of a 3D human lymphoid microenvironment model in vitro. Cell reports methods, 5(7), 101105.

David M, et al. (2025) Enhanced anti-tumor activity by zinc finger repressor-driven epigenetic silencing of immune checkpoints and TGFBR2 in CAR-T cells and TILs. Molecular therapy. Oncology, 33(2), 200989.

Weber J, et al. (2025) ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice. Cell reports. Medicine, 6(10), 102400.

Giraud J, et al. (2024) THBS1+ myeloid cells expand in SLD hepatocellular carcinoma and contribute to immunosuppression and unfavorable prognosis through TREM1. Cell reports, 43(2), 113773.

Bernardes JP, et al. (2020) Longitudinal Multi-omics Analyses Identify Responses of Megakaryocytes, Erythroid Cells, and Plasmablasts as Hallmarks of Severe COVID-19. Immunity, 53(6), 1296.